Ocuphire Pharma to acquire Opus Genetics.

Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of patients with retinal and refractive eye disorders, agreed to acquire Opus Genetics, a clinical-stage gene therapy company for inherited retinal diseases. Financial terms were not disclosed. “With the Ocuphire team’s late-stage ophthalmic drug development and regulatory approval experience and resources, we believe we are well-positioned to accelerate our pipeline of potentially transformative gene therapies for inherited retinal diseases. We see this transaction as a win for patients with IRDs around the world, and we look forward to efficiently progressing our combined pipeline,” Ben Yerxa, Ph.D., Opus Genetics former President and CEO and President of the newly combined company.